Baseline Variables | Complete Cohort | Participants at 15-year Followup | p |
---|---|---|---|
Demographic | |||
Age, yrs | 51.9/54.00 (22–70) | 47.3/48.0 (22–70) | <0.001 |
Female sex | 175 (73.5) | 83 (76.9) | 0.29 |
RA disease duration, yrs | 2.3 (0–4) | 2.2 (0–4) | 0.55 |
Biomarkers | |||
CRP, mg/l | 10.08/5.31 (12.71) | 8.63/3.80 (11.61) | 0.01 |
ESR | 25.89/20.50 (19.77) | 22.84/16.50 (20.11) | 0.003 |
IgM RF-positive | 114 (47.9) | 44 (40.7) | 0.04 |
Anti-CCP-positive | 144 (60.5) | 59 (54.6) | 0.09 |
Disease activity | |||
Ritchie score | 9.77/8.50 (5.98) | 9.54/8.00 (5.81) | 0.50 |
Medication | |||
MTX user at baseline | 48 (20.2) | 21 (19.4) | 0.80 |
Glucocorticoid user at baseline | 65 (27.3) | 22 (20.4) | 0.03 |
Mean/median (SD) reported for continuous variables, mean/median (range) for age, numbers (%) for counts. CRP: high sensitivity C-reactive protein; ESR: erythrocyte sedimentation rate; RF-positive: rheumatoid factor ≥ 25 U/ml; anti-CCP-positive: anti-cyclic citrullinated peptide ≥ 25 U/ml.